Oral ingestion has been the most convenient and commonly used route of drug administration because of its flexibility and dosage form design (1). In the immediate release (IR) dosage form, there is little or no control of drug release from the dosage form, which often results in constantly changing, unpredictable, and often sub- and supra-the-
rapeutic plasma concentrations (2). Controlled release (CR) systems have been introduced to overcome the drawback associated with IR dosage forms. Among the various CR formulations available, per-oral controlled release (CR) holds the major market share because of its advantages such as ease of administration and better patient compliance (3).

The majority of per-oral CR dosage forms fall in the category of matrix, reservoir or osmotic systems. Drug release from matrix and reservoir systems is affected by pH, hydrodynamic conditions and the presence of food in the gastro-intestinal tract (2). Osmotic systems utilize the principles of osmotic pressure for controlled delivery of drugs (4). Drug release from these systems is to a large extent independent of pH and other physiological parameters (5). The development of oral osmotic systems has a large market potential, as evident from the marketed products and number of patents granted in the last few years (6, 7).

Tramadol hydrochloride (TRH), a centrally acting opioid analgesic, is used in severe acute or chronic pains (8). It offers several therapeutic advantages over other analgesics, such as good oral bioavailability and long elimination half-life (5–7 h). Despite the long elimination half-life, TRH is prescribed 3–4 times a day (9). Frequent dosing schedule often leads to decreased patient compliance, increased incidence of side effects and tolerance development, especially, in long-term use (10) in conditions like arthritis, osteoarthritis, arthralgia, postoperative surgical pains, etc. It seems that there is a strong clinical need and market potential for a delivery system that can deliver TRH in a controlled manner.

The present study was thus aimed at the development of extended release formulation of TRH based on osmotic technology.

EXPERIMENTAL

Materials

Tramadol hydrochloride (98.7 % purity) was obtained from Win Medicare Ltd, India. Polyethylene oxide (Mₐ 300000) was received from Torrent Research Centre, India. The following chemicals and excipients were purchased from commercial sources and were used as such: cellulose acetate (39.8 % acetylation), polyvinyl pyrrolidone (PVP K-30), microcrystalline cellulose (MCC pH 102), magnesium stearate, talc, sodium chloride (all from CDH, India), acetone, methanol (HPLC grade), acetonitrile (HPLC grade), triethanolamine, fructose, mannitol (all from Qualigens Fine Chemicals, India), disodium hydrogen orthophosphate, orthophosphoric acid (all from S.D. Fine Chemicals, India). TRD CONTIN® (Modi-Mundi Pharmaceuticals, India, 100 mg sustained release tablet) and Tramazac® (Zydus Cadila Pharmaceuticals, India, 50 mg conventional tablet) were purchased from a retail pharmacy.

Formulation development

Before initiating formulation development, compatibility of TRH with different excipients was tested using the techniques of DSC (Du-Pont, Model 9900, USA) and FT-IR (Shimadzu, Model 8400S, Japan). Excipients used in the final formulation were found to be compatible with TRH.
Core tablets of TRH were prepared by direct compression and batch size was 100 tablets. Formulas of different core formulations of TRH are listed in Table I. TRH was mixed with polyethylene oxide (PEO) for 10 min. After passing this mixture through a sieve 600 μm, osmotic agents (fructose or mannitol), MCC and PVP were added in geometric dilution and mixing continued for an additional 10 min. To this mix, talc and magnesium stearate passed through 250 μm sieve, were added and mixing continued for an additional 10 min. The blend was then compressed into tablets of average mass of 300–320 mg using a single station tablet punching machine (Manesty E-2, UK) fitted with 8 mm round standard concave punches. The punched tablets were of 6.0 ± 0.38 kg cm⁻² hardness on the Monsanto hardness tester (Campbell Electronics, India).

TRH core tablets were coated in a conventional laboratory coating pan (Scientific Instrument, India) fitted with three baffles placed at an angle of 120° having the outer diameter of 10 cm (11). The composition of solutions used for coating TRH tablets is given in Table II. The coating process was done on a batch of 100 tablets; pan speed was maintained at 20 rpm and hot air inlet temperature was kept at 38–42 °C (11). The manual coating procedure based on intermittent spraying and coating was used at a spray rate of 4–5 mL min⁻¹. Coat mass and thickness were controlled by the volume of coating solution.

**Table I. Formula for different batches of core formulation**

<table>
<thead>
<tr>
<th>Ingredients (mg per tablet)</th>
<th>Batch number</th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
<th>V&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tramadol hydrochloride</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Mannitol</td>
<td>–</td>
<td>136</td>
<td>136</td>
<td>136</td>
<td>136</td>
<td>136</td>
</tr>
<tr>
<td>Fructose</td>
<td>136</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>PEO</td>
<td>–</td>
<td>–</td>
<td>30</td>
<td>50</td>
<td>70</td>
<td>–</td>
</tr>
<tr>
<td>MCC</td>
<td>50</td>
<td>50</td>
<td>20</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>PVP</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Talc</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

PEO – polyethylene oxide, MCC (pH 102) – microcrystalline cellulose, PVP K-30 – polyvinylpyrrolidone

<sup>a</sup> Batch with average mass of 320 mg. Other batches are of average mass 300 mg.

**Table II. Composition of coating solutions**

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Coat code</th>
<th>A</th>
<th>B</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose acetate (mg)</td>
<td>4000</td>
<td>4000</td>
<td>4000</td>
<td></td>
</tr>
<tr>
<td>PEG-400 (mg)</td>
<td>–</td>
<td>400</td>
<td>800</td>
<td></td>
</tr>
<tr>
<td>Methanol (mL)</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Acetone (mL)</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td></td>
</tr>
</tbody>
</table>
solution consumed in the coating process (11). Coating was continued until the desired coat thickness (150 μm) was obtained on the core tablets. An appropriate size orifice (0.5 mm) was made on one face of all the coated tablets using a microdrill (Kamlesh Engineers, India) (12). In all the cases, coated tablets were dried at 50 °C for 10 h before further evaluation.

**Surface morphology study**

To investigate the changes in the membrane structure due to the presence of plasticizer (PEG-400), the surface of coated tablets (both before and after dissolution studies) was studied using SEM (JEOL, JSM-6100, Japan). The samples were placed on a spherical brass stub (12 mm diameter) with a double backed adhesive tape. The mounted samples were sputter coated for 5 to 10 min with gold using a fine coat ion sputter (Jeol, JFC-1100, Japan) and examined under SEM (Jeol, JSM-6100, Japan).

**Evaluation of developed formulation**

Bulk and tap density of the powdered blend was determined using the USP method II (13) and the compressibility index and Hausner ratio were calculated.

The core and coated tablets were evaluated for mass variation. Thickness and diameter of the core and coated tablets were measured using screw gauze (Ultra Science Aid, India). Hardness of randomly selected tablets was tested using a hardness tester (Monsanto hardness tester). Friability of 20 core tablets was carried out on a Cintex friability test apparatus (Cintex, India).

The developed formulation (n = 3) of TRH was subjected to release studies using a USP dissolution apparatus type II (Campbell Electronics, India) at 50 rpm (13). Dissolution medium used was simulated intestinal fluid (SIF) (pH 6.8, 900 mL) maintained at 37 ± 0.5 °C, which was found to provide sink conditions (solubility of TRH was determined to be > 0.5 g mL⁻¹) (14). The samples were withdrawn (5 mL) at different time intervals and replaced with equivalent amounts of fresh medium. Dissolution samples, after filtration through a 0.45-μm nylon membrane filter, were analyzed using an already reported validated HPLC method at 271 nm (15, 16). After analyzing the drug content in the dissolution samples, corrections were made for volume replacement and the graph of cumulative percent of drug release vs. time was plotted.

Release profiles of various batches were compared using a model independent pairwise approach, which includes calculation of the 'difference factor' f₁ and 'similarity factor' f₂. The two release profiles were considered to be similar if f₁ value was lower than 15 (between 0 and 15) and f₂ value was more than 50 (between 50 and 100). Release profiles were also compared using the mean dissolution time (MDT), which was calculated using the following equation (17):

\[
MDT = \frac{\sum_{j=1}^{n} t_j \Delta M_j}{\sum_{j=1}^{n} \Delta M_j}
\]
where \( j \) is the sample number, \( n \) is the number of dissolution sample times, \( t^j \) is the time at mid-point between \( t_j \) and \( t^{(j-1)} \), and \( \Delta M_j \) is the additional amount of drug dissolved between \( t_j \) and \( t^{(j-1)} \). One-way analysis of variance test (ANOVA) was performed to check whether there was a significant difference between different formulations.

In this study, the mean dissolution time for 50 \( \% \) drug release (\( MDT_{50} \)) was used for comparison of release profiles from different batches.

For content uniformity testing, accurately weighed tablets \( (n = 20) \) were dissolved in 500 mL of distilled water (18). The samples were sonicated for 30 min and filtered through a 0.45-\( \mu \)m nylon membrane filter. The filtered samples, after appropriate dilution with the mobile phase, were analyzed at 271 nm using HPLC (Cecil HPLC system, UK).

**HPLC analysis**

For *in vitro* and *in vivo* analysis of drug samples, the Cecil HPLC system equipped with an adept series dual piston pump CE-4100, manual injector Caplugs RC-11 and adept series variable wavelength UV/Vis detector CE-4201 was used. Reverse phase HPLC method was carried out using a phenomenex C-18 column (4.6 \( \times \) 250 mm, 5 mm particle size) at 25 \( ^\circ \)C. The optimized mobile phase composition was phosphate buffer (0.01 mol L\(^{-1}\))/acetonitrile/triethanolamine (75:25:0.1) at a flow rate of 1 mL min\(^{-1}\). Injected volume was 20 mL and detection was performed at 271 nm (15, 16).

**In vivo studies**

*In vivo* studies were performed following the standard protocols on six healthy human volunteers of either sex weighing 55–75 kg and 24–29 years old in a crossover design with a wash-out period of one week. Volunteers agreed in writing to participate in the study after being informed about the experimental protocol. All the subjects were in good health according to their medical history and complete medical examination. Heparinized blood samples were taken at the following times: 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h post administration and stored at \(-4\) \( ^\circ \)C till further used.

The experimental protocol was approved by the human ethical committee, Banaras Hindu University, India.

Plasma samples were prepared by liquid-liquid extraction. Plasma (250 \( \mu \)L) was mixed with 100 \( \mu \)L NaOH (1 mol L\(^{-1}\)) in a 4-mL test tube and then extracted with 1.25 mL of ethyl acetate. After vertical agitation (10 min) and centrifugation (10,000 rpm, 10 min), the upper organic layer was transferred into a conical glass tube. Extraction was repeated using another 1.25 mL of ethyl acetate. The organic phase was then evaporated under a gentle stream of air and reconstituted in 250 \( \mu \)L of a mobile phase (15, 16).

**In vitro–in vivo correlation**

*In vitro–in vivo* correlation of the optimized batch was investigated by plotting the percent dissolved (\( F_r \)) vs. percent absorbed (\( F_a \)) drug. Percent dissolved values were taken from *in vitro* release data and percent absorbed was determined by the Wagner-Nelson method using the following equation (19):
\[ F_a = \left[ \left( C_t + k_e \text{AUC}_{0-t} \right) / k_e \text{AUC}_{0-\infty} \right] \times 100 \]  

\[ \text{AUC}_{0-\infty} \]

where \( F_a \) is the fraction of drug absorbed, \( C_t \) is the drug plasma concentration at time \( t \), \( k_e \) is the overall elimination rate constant, \( \text{AUC}_{0-t} \) and \( \text{AUC}_{0-\infty} \) are areas under the curve between time zero and time \( t \) and between time zero and infinity, respectively.

RESULTS AND DISCUSSION

**Desired drug release profile**

Using the different pharmacokinetic parameters of TRH (Table III), the dose needed to provide controlled delivery of TRH can be calculated by the following equation (20):

\[ D_0 = C_p T C_l T \]  

where \( D_0 \) is the dose, \( C_p \) is the therapeutic drug plasma level, \( C_l T \) is total clearance and \( T \) is the dosing interval. Therapeutic range for TRH is reported to be between 0.1–0.3 \( \mu g \) mL\(^{-1}\) (21) and the desired steady state concentration of TRH for a 100 mg (four times a day) dose is 0.225 \( \mu g \) mL\(^{-1}\). Taking the steady state concentration as the desired therapeutic plasma level and the dosing interval of 12 h, the following values were proposed: (i) sustaining dose 100 mg, (ii) zero-order release rate 8.1 mg h\(^{-1}\), (iii) dosing interval 12 h. By plotting the cumulative zero-order release (%) (\( y \)) vs. time (\( x \)), the desired release profile was generated and used as the target release profile for developed formulations (\( y = 8.1x \)).

**Effect of formulation variables**

In the initial trial, TRH core tablets (batch I) were coated with the coating composition code B (formulation code batch IB). Release studies showed that more than 85 % of the drug was delivered within 5 h (Fig. 1). This may be due to the high solubility of TRH or high osmotic pressure generation within the core compartment. To reduce the osmotic

<table>
<thead>
<tr>
<th>Pharmacokinetic parameter</th>
<th>Value</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioavailability (( f ))</td>
<td>74 %</td>
<td>8, 9</td>
</tr>
<tr>
<td>Elimination half-life (( t_{1/2} ))</td>
<td>6.3 h</td>
<td>9, 10</td>
</tr>
<tr>
<td>Terminal disposition rate constant (( K_{el} ))</td>
<td>0.11 h(^{-1})</td>
<td>8–10</td>
</tr>
<tr>
<td>Apparent volume of distribution (( V_d ))</td>
<td>2.7 l kg(^{-1})</td>
<td>8, 9</td>
</tr>
<tr>
<td>Maximum effective conc. (( c_{max} ))</td>
<td>0.3 ( \mu g ) mL(^{-1})</td>
<td>22</td>
</tr>
<tr>
<td>Minimum effective conc. (( c_{min} ))</td>
<td>0.1 ( \mu g ) mL(^{-1})</td>
<td>22</td>
</tr>
<tr>
<td>Total clearance (( C_l T ))</td>
<td>8.5 mL min(^{-1}) kg(^{-1})</td>
<td>8–10</td>
</tr>
</tbody>
</table>
pressure in the core compartment, mannitol (38 atm, saturated solution) (7) was used in place of fructose (335 atm, saturated solution) (7) within the core (batch IIB). This approach was unsuccessful as more than 75% drug was released within 5 h (Fig. 1).

Osmotic pumps per se are suitable for the delivery of drugs having intermediate water solubility (2). It has been reported that in case of water-insoluble drugs, reasonable release rates may not be obtained using an elementary osmotic pump or controlled-porosity osmotic pump (5). This is because the kinetics of osmotic drug release is directly related to drug solubility within the core. Assuming a tablet core of pure drug, the fraction of drug released with zero-order kinetics is given by:

$$F(z) = 1 - \frac{S}{\rho}$$

where $F(z)$ is the fraction released by zero-order kinetics, $S$ is the drug solubility (g mL$^{-1}$), and $\rho$ is the density (g mL$^{-1}$) of the core tablet. Drugs with a solubility of $\leq 0.05$ g mL$^{-1}$ would be released with $\geq 95\%$ zero-order kinetics according to Eq. (4). However, the zero-order release rate would be slow according to Eq. (5), due to the small osmotic pressure gradient:

$$\frac{dm}{dt} = \frac{A}{h} \sigma L_p (\Delta \pi - p)C$$

Eq. (5) describes drug release from osmotic pumps, where $dm/dt$ is the drug delivery rate, $A$ and $h$ are the membrane area and thickness, respectively, $c$ is the concentration (or the solubility, when excess of drug is present in the core) of the drug in the dispersed fluid, $\Delta \pi$ is the osmotic pressure difference across the film, $\sigma L_p$ is the hydraulic permeability of the membrane and $p$ is the hydrostatic pressure within the core compartment.

According to Eq. (4), highly water-soluble drugs would demonstrate a high release rate, which would be zero-order for a small percentage of the initial drug load. Thus, the...
intrinsic water solubility of many drugs might preclude them from incorporation into an osmotic pump. However, it is possible to modulate the solubility of drugs within the core, and thus extend this technology for delivery of drugs that may otherwise be poor candidates for osmotic delivery.

TRH is a basic drug with very high water solubility; $pK_a$ value of TRH is 9.41, hence solubility is also pH independent at physiological pH (11). In order to get the desired release from the developed systems, PEO was added to the core formulation. After coming in contact with the surrounding fluid, swellable polymer (PEO) causes significant swelling, which creates significant internal pressure within the osmotic system leading to reduced imbibition. Also, the PEO within the core may restrict or delay the contact of solvent molecules with the drug and osmotic agent molecules, which may result in decreased osmotic pressure generation within the device and thus control the release of the drug from EOP (22, 23). Three batches were prepared, in which the PEO concentration was varied. Batches III, IV and V were coated with the coating composition code B and formulations coded as batch IIIB, IVB, VB containing 10 %, 16.6 %, and 23.3 % (m/m) of PEO respectively. In vitro release profiles of three batches (IIIB, IVB, VB) compared to batch IIB (without PEO) are compared in Fig. 1. It is clearly evident that the concentration of PEO has an inverse effect on drug release. With an increase in the PEO concentration within the core there was a decrease in drug release and an increase in swelling of the formulations due to higher internal pressure generated by PEO. The differences in $MDT_{50}$ between the above formulations (1.44, 2.56, 3.01, 3.57 h for batch IIB, IIIB, IVB and VB, resp.) were found to be statistically significant ($p < 0.05$).

To study the effect of coat thickness of the semipermeable membrane (SPM) on drug release, core tablets of TRH (batch IV) were coated with the coating composition code B so as to give coat thickness of 100, 150 and 200 μm. Release profiles of TRH from these formulations are shown in Fig. 1. It is clearly evident that drug release decreases with the increase in coat thickness of SPM. The differences in $MDT_{50}$ between the above formulations (2.56, 3.19, 4.12 h for 100–150- and 200-μm coat thickness) were found to be statistically significant ($p < 0.05$).

To study the effect of the level of plasticizer (PEG-400), core formulation (batch IV) of TRH was coated with coating composition code A and C with no PEG-400 and containing 20 % (m/m) PEG-400 (of cellulose acetate mass), respectively (batches IVA and IVC). Release profiles of these formulations in comparison with batch IVB [containing 10 % (m/m) PEG-400 of cellulose acetate mass] are shown in Fig. 1. It is clearly evident that the level of plasticizer, PEG-400, has a direct effect on drug release. As the level of PEG-400 increases, the membrane becomes more porous due to rapid dissolution of water soluble PEG-400 in dissolution medium, resulting in higher drug release (11).

In vitro drug release profiles of the promising batches IIIB, IVB and VB were compared with commercial immediate release Tramazac®-50 mg (M1) and sustained release TRD-CONTIN®-100 mg (M2) formulations of TRH and also with the theoretically desired release profile (Fig. 2). It is clearly evident that the developed formulations provided more controlled and prolonged drug release compared to commercial formulations of TRH. Drug release from batch IVB was found to be closest to the desired release profile. The $f_1$ and $f_2$ values for batch IVB were 5.71 and 82.31, respectively, taking the desired release profile as reference, indicating no significant difference between batch IVB.
and the theoretically desired release profile. Formulation IVB was therefore selected as the optimized formulation and was further evaluated.

**Evaluation of the optimized formulation**

The optimized batch IVB was evaluated for various pharmacopoeial and non-pharmacopoeial tests, results of which are listed in Table IV. The powder blend was free flowing, as demonstrated by the values of the compressibility index (less than 15) and Hausner ratio (less than 1.25). Exhausted shells, after dissolution, were visually observed for any imperfection or cracks in the coating. There were no visible cracks in the coating and it was found to be intact in all batches after 8 h of dissolution studies.

To study the effect of pH and to assure a reliable performance, release studies of the optimized formulation were conducted according to the pH change method (initial 2 h

![Fig. 2. Comparison of promising formulations with commercial formulations and the theoretically desired release profile. Points represent mean ± SD (n = 3).](image)

![Fig. 3. Effect of pH, agitation intensity and osmotic pressure of dissolution medium on TRH release from developed formulations. Points represent mean ± SD (n = 3).](image)
in pH 1.2, next 2 h in pH 4.5, 2 h in pH 6.8 and finally 2 h in pH 7.4) and compared to release data in SIF. There was a not a significant difference between different pHs of release medium on TRH release compared to \textit{in vitro} data in SIF (Fig. 3). The $f_1$ and $f_2$ values of batch IVB were found to be 2.65 and 91.85 respectively, taking the release profile in SIF as reference.

To study the effect of hydrodynamic conditions on TRH release, a release study of batch IVB was carried out at three different rotational paddle speeds (50, 100, 150 rpm). There was an insignificant effect of rotational speed on TRH release from developed formulations when all the three release profiles were compared (Fig. 3). The $f_1$ and $f_2$ values were found to be 4.22 and 85.09 (between 50 and 100 rpm), 3.71 and 85.78 (between 100 and 150 rpm), and 7.77 and 73.33 (between 50 and 150 rpm), respectively.

To study the effect of osmotic pressure, release studies of the optimized formulation were conducted in media of different osmotic pressure (19.12, 47.32, 94.64 atm). The results showed that the drug release was highly dependent on the osmotic pressure of the release media. TRH release from the formulations decreased as the osmotic pressure of the media increased (Fig. 3). Thus it was concluded that osmotic pumping is the major mechanism governing drug release from developed formulations.

Before dissolution studies, all membranes (Figs. 4a,b, and c) looked similar and no porous membrane structure was observed with different levels of plasticizer (PEG-400). Fig. 4b shows the SEM micrograph of a membrane with no PEG-400 (batch IVA). It shows a surface morphology similar to that of Fig. 4a, suggesting that there is no evidence of development of pores in the membrane after the dissolution study. On the other hand,

\begin{table}
\caption{Properties of the powdered blend, core tablets, and final coated tablets of the optimized formulation (batch IVB)}
\begin{center}
\begin{tabular}{lcc}
\hline Parameter & Mean value (± SD) \\
\hline Bulk density (mg mL\textsuperscript{-1})\textsuperscript{a} & 415 \\
Tap density (mg mL\textsuperscript{-1})\textsuperscript{a} & 464 \\
Compressibility index (%)\textsuperscript{a} & 8.69 \\
Hausner ratio\textsuperscript{a} & 1.08 \\
Core tablet mass (mg, $n = 10$) & 300.12 (± 5.21) \\
Coated tablet mass (mg, $n = 10$) & 318.21 (± 4.62) \\
Core tablet thickness (mm, $n = 10$) & 4.12 (± 0.02) \\
Coated tablet thickness (mm, $n = 10$) & 4.48 (± 0.02) \\
Core tablet diameter (mm, $n = 10$) & 8.11 (± 0.11) \\
Coated tablet diameter (mm, $n = 10$) & 8.32 (± 0.02) \\
Core tablet hardness (kg cm\textsuperscript{-2}, $n = 10$) & 6.12 (± 1.12) \\
Coated tablet hardness (kg cm\textsuperscript{-2}, $n = 10$) & 10.24 (± 1.48) \\
Friability (%,$n = 20$)\textsuperscript{b} & 0.096 \\
Content uniformity (%,$n = 20$)\textsuperscript{c} & 102.46 (± 2.24) \\
\hline
\end{tabular}
\end{center}
\textsuperscript{a} Property of powdered blend; \textsuperscript{b} property of core tablet; \textsuperscript{c} Property of final coated tablet.
there was formation of pores in membranes of batches IVB and IVC (Figs. 4d,f) after dissolution studies. This might be due to the rapid dissolution of the water soluble plasticizer (PEG-400) in dissolution medium. When comparison was made of the membranes containing different levels of plasticizer (Figs. 4b,d,f), it was found that the membrane that contained a higher level of plasticizer became more porous after the dissolution studies.

Fig. 4. SEM micrograph showing the membrane structure of formulation batches IVA, IVB and IVC (150 μm coat thickness). Panels a, c, and e represent SEM micrographs before the dissolution study of batches IVA, IVB and IVC, respectively, whereas panels b, d, and f represent SEM micrographs after the dissolution study of batches IVA, IVB and IVC, respectively.
Kinetics and mechanism of drug release

Dissolution data of the optimized formulation (batch IVB) was fitted to various mathematical models (zero-order, first-order and Higuchi) in order to describe the kinetics of drug release (17). Smallest value of the sum of squared residuals (SSR), Akaike information criterion (AIC) and the best goodness-of-fit test ($R^2$) were taken as criteria for selecting the most appropriate model. Drug release from optimized formulations fitted well into zero-order kinetics (Table V), confirming that the release from formulations is close to the desired release profile and drug load dependent.

Reproducibility and accelerated stability study

Reproducibility of the manufacturing procedure was confirmed by preparing three repeated batches of the final optimized formulation on three different occasions. Release studies were conducted in SIF and similar release profiles were obtained from all repeated batches, demonstrating that the manufacturing procedure is reproducible. The $f_1$ and $f_2$ values were found to be 4.11 and 85.07 (between repeat batches 1 and 2), 3.26 and 89.46 (between repeat batches 1 and 3), and 5.23 and 81.68 (between repeat batches 2 and 3), respectively.

Optimized TRH formulations were packed in strips of 0.04 mm thick aluminum foil laminated with polyvinyl chloride (PVC). Packed formulations were stored in stability chambers (Narang Scientific Work, India) maintained at 40 °C and 75 % relative humidity for 6 months (24). Stored formulations of optimized batch with 150-μm coat thickness were found to be stable in terms of physical properties, hardness, in vitro release characteristics and dissolution stability (Table VI) even after storage for 6 months. Despite statistically significant variability in the drug content, the tested formulation adhered to ICH (24) criterion of ≤ 5 % drug content change from its initial value.

In vivo study and in vitro-in vivo correlation

The plasma TRH concentration vs. time profile (Fig. 5) obtained from the in vivo study clearly shows that the developed formulations (batch IIIB and batch IVB) maintained a constant therapeutic TRH concentration within the plasma even up to 24 h, as compared

Table V. Fitting drug release of the optimized formulation (batch IVB) according to various mathematical models

<table>
<thead>
<tr>
<th>Model</th>
<th>Parameters used</th>
<th>R</th>
<th>Intercept (%)</th>
<th>Slope (% h⁻¹)</th>
<th>$k_a$</th>
<th>SSR</th>
<th>AIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zero-order</td>
<td></td>
<td>0.9996</td>
<td>2.9071</td>
<td>9.423</td>
<td>8.371</td>
<td>25.8</td>
<td>15.36</td>
</tr>
<tr>
<td>First-order</td>
<td></td>
<td>0.9370</td>
<td>1.9157</td>
<td>0.332</td>
<td>0.3326</td>
<td>216.12</td>
<td>32.36</td>
</tr>
<tr>
<td>Higuchi model</td>
<td></td>
<td>0.9903</td>
<td>36.8103</td>
<td>37.359</td>
<td>37.359</td>
<td>128.42</td>
<td>26.18</td>
</tr>
</tbody>
</table>

$R$ – correlation coefficient, SSR – sum of squares of residuals, AIC – Akaike information criteria, $k$ – release rate constant for respective models, $a k_a$ in mg h⁻¹, $k_1$ in h⁻¹ and $k_H$ in % h⁻¹/² for zero-order, first order and Higuchi rate equations models respectively.
to commercial formulations M1 and M2, which showed a rapid decline in drug concentration with time. The developed formulations showed lower $c_{\text{max}}$ (but within therapeutic range) and higher $t_{\text{max}}$ values than commercial tablets (Table VII). Lower $c_{\text{max}}$ for batches IIIB and IVB indicate avoidance of the risk of exceeding the maximum safe concentration. Higher $t_{\text{max}}$ for batches IIIB and IVB is indicative of drug release occurring at a slower rate than from commercial tablets. Significantly higher value of $\text{AUC}_{0-24}$, relative bioavailability and mean residence time ($\text{MRT}$) for batch IVB compared to M1 and M2 (Table VII) further indicate the superiority of the developed formulation over commercial immediate release (M1) and sustained release (M2) tablets of TRH, in terms of providing controlled drug release for a longer time and improved bioavailability.

An in vitro-in vivo correlation of batch IVB was carried out using the Wagner-Nelson method (20). Percent drug dissolved (x) when plotted against percent drug absorbed (y) gives a good linear regression $y = 1.49x + 7.838$ (Table VIII). The correlation coefficient $R$ of 0.9750 indicates a good correlation up to almost 54 % in vitro drug release.

### Table VI. Batch IVB stability$^a$

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Initial</th>
<th>2 month</th>
<th>4 month</th>
<th>6 month</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug content (% ± SD, $n = 20$)</td>
<td>102.60 ± 1.44</td>
<td>99.68 ± 1.87$^b$</td>
<td>98.14 ± 1.67$^b$</td>
<td>104.60 ± 1.61$^b$</td>
</tr>
<tr>
<td>Hardness (mean ± SD, $n = 10$)</td>
<td>7.33 ± 1.98</td>
<td>7.98 ± 1.68</td>
<td>7.33 ± 1.48</td>
<td>8.13 ± 1.52</td>
</tr>
<tr>
<td>$f1$</td>
<td>–</td>
<td>2.32</td>
<td>4.52</td>
<td>5.12</td>
</tr>
<tr>
<td>$f2$</td>
<td>–</td>
<td>92.62</td>
<td>84.62</td>
<td>82.24</td>
</tr>
<tr>
<td>$MDT_{50}$</td>
<td>3.004</td>
<td>3.271</td>
<td>3.151</td>
<td>3.208</td>
</tr>
</tbody>
</table>

$^a$ 6 months storage at 40 °C and 75 % RH
$^b$ Significant difference ($p < 0.05$) vs. initial value.

Fig. 5. Plasma profiles of TRH following oral administration of developed formulations compared to commercial formulations to healthy human subjects. Points represent mean ± SD ($n = 6$).
CONCLUSIONS

Extended release formulations of TRH were developed based on osmotic technology. The effect of different formulation variables was studied to optimize the release profile. Drug release was directly proportional to the level of plasticizer, but inversely related to the level of swellable polymer and membrane thickness. Release from the developed formulations was independent of pH and agitation intensity of the release media, assuring the release to be fairly independent of pH and hydrodynamic conditions of the absorption site. TRH release from the developed formulations was inversely proportional to the osmotic pressure of the release media, confirming osmotic pumping to be the major mechanism of drug release. The in vivo study showed that the optimized formulation (batch IV) achieved a higher value of $AUC_{0-24}$, relative bioavailability and $MRT$ compared to the commercial formulation of TRH. This study suggests that the developed optimized formulation (IVB) could perform therapeutically much better than the commercial immediate release (M1) and sustained release (M2) tablets of TRH as potential prolonged and controlled release dosage forms.
REFERENCES


